VitaNova Life Sciences (VNOV) Net Margin (2017 - 2026)

VitaNova Life Sciences has reported Net Margin for 7 years, with the latest figure at 6.25% in Q1 2026.

• For the quarter ending Q1 2026, Net Margin fell 2992.0% year-over-year to 6.25%; the trailing twelve-month figure through Jan 2026 stood at 23.34% (up 592.0% YoY), and the FY2025 full-year result was 31.96%, up 727.0% from the prior year.
• Net Margin for Q1 2026 stood at 6.25%, down from 8.38% in the prior quarter.
• The five-year high for Net Margin was 40.98% in Q2 2025, with the low at 245.77% in Q1 2023.
• Historically, Net Margin has averaged 23.03% across 5 years, with a median of 11.18% in 2024.
• Annual changes were most pronounced in 2023 — Net Margin tumbled 27549 bps — and 2024, when it surged 26856 bps.
• VitaNova Life Sciences' Net Margin stood at 26.01% in 2022, then sank by 662 bps to 146.17% in 2023, then surged by 108 bps to 11.18% in 2024, then retreated by 25 bps to 8.38% in 2025, then plunged by 175 bps to 6.25% in 2026.
• The last three Net Margin figures came in at 6.25% (Q1 2026), 8.38% (Q4 2025), and 44.56% (Q3 2025), per Business Quant data.